Hedgehog trial results suggest antitumor activity in basal cell skin cancer
A Phase I clinical trial tested GDC-0449, a Hedgehog Pathway Inhibitor, and demonstrated tumor shrinkage and limited side effects in patients with locally-advanced and metastatic basal cell carcinoma. The study's results suggest a durable clinical benefit, offering hope for patients with advanced skin cancer.